About Polaris
Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans.
The company's lead therapeutic, ADI-PEG 20, is in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris is also investigating ADI-PEG 20 as a treatment for other arginine-dependent cancers, such as metastatic melanoma, prostate cancer, leukemia, lymphoma, sarcoma and pancreatic cancer.
Polaris is researching and developing other biotherapeutic agents and has a small molecule drug program that utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.
News
-
February 03, 2015
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus FOLFOX in Advanced Gastrointestinal Malignancies
-
December 18, 2014
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma
-
December 10, 2014
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 Plus Sorafenib in Advanced Hepatocellular Carcinoma
-
December 03, 2014
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer
-
November 20, 2014
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma
-
November 18, 2014
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Doxorubicin in HER2 Negative Breast Cancer
-
April 29, 2014
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Induces Alterations in Gene Expression and Demonstrates Potential Anticancer Activity in Non-Small Cell Lung Cancers, Malignant Pleural Mesothelioma and Melanomas, Cancers That Are Deficient in Key Metabolic Protein
-
April 02, 2014
Shaw T. Chen, M.D., Ph.D. Joins Polaris as Executive VP of Regulatory Affairs